Annual Drug Patent Expirations for BRILINTA
Brilinta is a drug marketed by Astrazeneca and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug and two Paragraph IV challenges.
Drug patent litigation for BRILINTA.
This drug has one hundred and thirty-four patent family members in forty-four countries.
The generic ingredient in BRILINTA is ticagrelor. Two suppliers are listed for this compound. Additional details are available on the ticagrelor profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
